Detection and Prevention of Cancer-Related Cardiovascular Toxicity Registry
- Conditions
- Cancer Related Cardiovascular Toxicity
- Interventions
- Combination Product: Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy
- Registration Number
- NCT06086132
- Lead Sponsor
- University of Bologna
- Brief Summary
This study is being done in order to assess the cardiovascular events known as cardiovascular toxicity of chemotherapy agents and radiotherapy protocols in cancer subjects to identify risk prediction, prevention and treatment of cancer therapy-related cardiovascular toxicity and cancer therapy-related cardiac dysfunction
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- NOT_YET_RECRUITING
- Sex
- All
- Target Recruitment
- 10000
- Age 18 years old or older
- Capable of giving informed consent
- Diagnosis of cancer scheduled for treatment according to treating physician's discretion
- Life expectancy >1 year
- For the prospective validation of HFA-ICOS risk score validation: Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs
- Age <18 years old
- Not able to give informed consent
- Life expectancy <1 year
- Advanced-stage cancer not eligible for treatment (subjects with an indication of palliative care) according to treating physician's
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description Breast cancer Prospective validation of the HFA-ICOS risk score in a subset of subjects with newly diagnosed breast cancer and undergoing treatment with anthracyclines analogues with or without radiotherapy Newly diagnosed breast cancer undergoing treatment with anthracyclines analogues with or without radiotherapy, with or without trastuzumab, or other anticancer drugs. (Non-interventional prospective patient registry)
- Primary Outcome Measures
Name Time Method All causes mortality For approximately a median of 3 years Occurrence of all cause death
Cardiovascular mortality For approximately a median of 3 years Occurrence of cardiovascular mortality
Cancer therapy-related cardiovascular toxicity For approximately a median of 3 years Occurrence of cancer therapy-related cardiovascular toxicity
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (5)
University of Bologna
🇮🇹Bologna, Italy
Azienda Ospedaliera Universitaria Policlinico "Paolo Giaccone"
🇮🇹Palermo, Italy
University of Belgrade, Clinical Hospital Center Bezanijska kosa
🇷🇸Belgrade, Serbia
University of Belgrade, Clinical Center of Serbia
🇷🇸Belgrade, Serbia
Ss. Cyril and Methodius University in Skopje, University Clinic
🇲🇰Skopje, North Macedonia